Skip to main content
Caplight Logo









AlgiPharma AS

AlgiPharma AS

Private
NorwayHealthcare & Life Scienceshttps://algipharma.com/

Last Round

Grant

Dec 20, 2021

Total Funding Raised

$23.57M

Company Overview

AlgiPharma AS is a biopharmaceutical company that develops proprietary alginate technology for drug delivery platforms, drug conjugates, and therapeutic applications in areas such as cystic fibrosis, COPD, and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalalginate oligosaccharidesmucosal healthcystic fibrosis treatmentchronic infectiondrug developmentclinical trialsbiotechmucus clearancedrug deliverytherapeutic candidateAPIorphan drugrespiratory medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AlgiPharma AS Comparables

Compare AlgiPharma AS with similar companies based on industry and business-model similarity.

AlgiPharma AS comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Renovion, Inc.
82%
Enterprise Therapeutics
80%
Aer Therapeutics
77%

AlgiPharma AS Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 20, 2021
GrantJan 15, 2018
GrantJan 15, 2018
GrantJan 15, 2018
GrantJan 15, 2018
Grant
Jun 3, 2016

Key People

Founding team and executive leadership

Ole Tobias Fevang

CFO

Executive Team

AlgiPharma AS Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 6, 2026

    Monthly visitors increased 226% MoM, reaching 2.7K.

  • Jun 1, 2025

    Monthly visitors increased 912% MoM, reaching 1.7K.

AlgiPharma AS Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AlgiPharma AS Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AlgiPharma AS's valuation, stock price, and market status.

Firmographic Details

HeadquartersNorway
Employee Range11
Year Founded2006
Last FundingDec 20, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?